Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-human t-lymphocyte globulin (rabbit)
- Development stage
- Unknown
- Lead developer
- Neovii Pharmaceuticals
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IIT-ATLG-69 refers to a clinical development program by Neovii Pharmaceuticals involving their proprietary anti-human T-lymphocyte globulin (ATLG), commercially known as Grafalon. ATLG is a rabbit-derived polyclonal antibody that targets various T-cell surface antigens (such as CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, and CD45) as well as HLA class I and II molecules. Its primary mechanism of action involves the depletion of T-lymphocytes through complement-dependent cytotoxicity (CDC) and opsonization followed by phagocytosis. In the context of stem cell transplantation (SCT), it is used as part of the conditioning regimen to prevent graft-versus-host disease (GvHD) and graft rejection by suppressing the recipient's immune system and modulating the donor T-cell response. The IIT-ATLG-69 designation specifically relates to investigator-initiated trials, including the Phase 3 FORUM II study, which evaluates optimized dosing strategies for ATLG in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
- Brand names
- Grafalon
- Other names
- anti-thymocyte globulin (rabbit)ATGFORUM II
02
Targets
CD2 (T-cell Surface Antigen CD2)IL2RA (Interleukin-2 receptor alpha subunit)CD8A (CD8 alpha/beta Coreceptor)CD3 (T-cell surface glycoprotein CD3)LFA-1 (Integrin αLβ2)CD4 (T lymphocyte surface antigen)HLA-DR (Human leukocyte antigen DR)
Beyond the preview
Go deeper on anti-human t-lymphocyte globulin (rabbit).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-human t-lymphocyte globulin (rabbit).